stockrow
Friday 6 November 2026
Export COGT’s income statement to Excel — free account
Cogent Biosciences, Inc.
COGT Healthcare Biotechnology
- EPS
- +1.89%
- Free cash flow
- −42.0%
Quarter to June 2026, against a year earlier
31.60
2.02
+6.83%
Follow COGT
Alert me
Cogent Biosciences, Inc. (COGT) Revenue
Cogent Biosciences, Inc.'s revenue for fiscal 2020 was $7.9M, down 65.0% from $22.5M in fiscal 2019. Over the past ten years it has ranged from $3.0M (fiscal 2015) to $22.5M (fiscal 2019); the current reading is higher than 50% of that period. Cogent Biosciences, Inc. ranks 176th of 390 Biotechnology companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2020 | $7.9M | (65.02%) |
| FY2019 | $22.5M | 131.14% |
| FY2018 | $9.7M | 16.44% |
| FY2017 | $8.4M | 31.55% |
| FY2016 | $6.4M | 112.83% |
| FY2015 | $3.0M | — |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Sep 2020 | $312.0K | (40.91%) |
| Jun 2020 | $528.0K | (92.49%) |
| Mar 2020 | $7.0M | (54.01%) |
| Dec 2019 | $15.3M | 1,398.82% |
| 11 more quarters | Free account |
Against its own ten years
Low $3.0M
High $22.5M
Ten-year median
$8.1M
Current reading's percentile
50
Revenue against peers
| Company | Revenue |
|---|---|
| PTCT PTC Therapeutics, Inc. compare | $1.2B |
| TVTX Travere Therapeutics, Inc. compare | $651.0M |
| SRRK Scholar Rock Holding Corporation compare | $47.3M |
| CRSP CRISPR Therapeutics AG compare | $25.2M |
| COGT Cogent Biosciences, Inc. | $23.2M |
| DNTH Dianthus Therapeutics, Inc. compare | $2.7M |
| ERAS Erasca, Inc. compare | — |
| MANE Veradermics Incorporated compare | — |
| KOD Kodiak Sciences Inc. compare | — |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on COGT
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement